Early Follicular Phase Human Chorionic Gonadotropin Addition May Improve the Outcomes of In Vitro Fertilization/Intracytoplasmic Sperm Injection in Patients With "Unpredictable" Poor Response to Gonadotropin-Releasing Hormone Antagonist Protocol

被引:0
|
作者
Zhang, Chunhui [1 ]
Wu, Fangrong [1 ]
Wu, Zexuan [1 ]
Sun, Bolan [1 ]
Chen, Cheng [1 ]
Qian, Weiping [1 ]
机构
[1] Peking Univ, Reprod Med Ctr, Shenzhen Hosp, Shenzhen, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2021年 / 12卷
关键词
ovarian stimulation; unpredictable POR; in vitro fertilization; low-dose hCG; GnRH antagonist; CONTROLLED OVARIAN STIMULATION; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING-HORMONE; RECOMBINANT FSH; WOMEN; SUPPLEMENTATION; FERTILIZATION; GROWTH; CYCLE;
D O I
10.3389/fendo.2021.739773
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose To compare the effects of early and mid-late follicular phase administration of 150 IU of human chorionic gonadotropin (hCG) on gonadotropin-releasing hormone (GnRH) antagonist protocol in "unpredictable" poor ovarian response (POR) women undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment. Methods A retrospective single-center cohort study was conducted on 67 patients with "unpredictable" POR in their first IVF/ICSI cycle receiving GnRH antagonist protocol. Patients were treated with a second IVF/ICSI cycle using the same GnRH antagonist protocol with the same starting dose of recombinant follicle-stimulating hormone (rFSH) as the first cycle; a daily dose of 150 IU of hCG was administrated on either stimulation day 1 (Group A, n = 35) or day 6 (Group B, n = 32). The number of oocytes retrieved, number of usable embryos, serum level of estradiol (E-2) on day of hCG trigger, and clinical pregnant outcomes were studied. Results The addition of 150 IU of hCG on either the first day or sixth day of stimulation increases the serum level of E-2, luteinizing hormone (LH), and hCG on the day of hCG trigger. Only the use of 150 IU of hCG on the first stimulation day improved the number of oocytes retrieved, mature of oocytes, and usable embryos, but not the addition of hCG on stimulation day 6. Implantation rate, clinical pregnancy rate, and ongoing pregnancy rate showed an increasing trend in patients receiving 150 IU of hCG in the early phase compared with mid-late phase, even thought there was no statistically significant difference. Conclusions Our study demonstrated that adding 150 IU of hCG in subsequent GnRH antagonist cycle in "unpredictable" poor responders is associated with the improvement of response to stimulation. Furthermore, early follicular phase addition of 150 IU of hCG significantly increased the number of oocytes retrieved and usable embryos than did the mid-late addition of the same dose.
引用
收藏
页数:7
相关论文
共 32 条
  • [21] Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist
    Tavaniotou, A
    Albano, C
    Smitz, J
    Devroey, P
    FERTILITY AND STERILITY, 2002, 77 (04) : 733 - 737
  • [22] Vascular endothelial growth factor and inhibin A in follicular fluid of infertile patients who underwent in vitro fertilization with a gonadotropin-releasing hormone antagonist
    Cunha, JS
    Lemos, N
    Stein, N
    Laranjeira, A
    Passos, EP
    FERTILITY AND STERILITY, 2005, 83 (04) : 902 - 907
  • [23] Early and short follicular gonadotropin-releasing hormone antagonist supplementation improves the meiotic status and competence of retrieved oocytes in in vitro fertilization-embryo transfer cycles
    Younis, Johnny S.
    Soltsman, Sofia
    Izhaki, Ido
    Radin, Orit
    Bar-Ami, Shalom
    Ben-Ami, Moshe
    FERTILITY AND STERILITY, 2010, 94 (04) : 1350 - 1355
  • [24] A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection
    Takeuchi, S
    Minoura, H
    Shibahara, T
    Tsuiki, Y
    Noritaka, F
    Toyoda, N
    FERTILITY AND STERILITY, 2001, 76 (03) : 532 - 537
  • [25] Increased responsiveness may be associated with tripronuclear embryos in both conventional in vitro fertilization and intracytoplasmic sperm injection cycles using gonadotropin-releasing hormone agonist long protocols: A self-matched observational study
    Kim, Yong Jin
    Ku, Seung-Yup
    Jee, Byung Chul
    Suh, Chang Suk
    Kim, Seok Hyun
    Choi, Young Min
    Kim, Jung Gu
    Moon, Shin Yong
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2011, 37 (01) : 37 - 44
  • [26] Application value of Early-Follicular Phase Long-Acting Gonadotropin-Releasing Hormone Agonist Long Protocol in patients with resistant ovary syndrome
    Zhang, Fan
    Zhang, Huixia
    Du, Hui
    Li, Xin
    Jin, Haixia
    Li, Gang
    BMC PREGNANCY AND CHILDBIRTH, 2023, 23 (01)
  • [27] Application value of Early-Follicular Phase Long-Acting Gonadotropin-Releasing Hormone Agonist Long Protocol in patients with resistant ovary syndrome
    Fan Zhang
    Huixia Zhang
    Hui Du
    Xin Li
    Haixia Jin
    Gang Li
    BMC Pregnancy and Childbirth, 23
  • [28] Does the time interval between antimullerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study
    Polyzos, Nikolaos P.
    Nelson, Scott M.
    Stoop, Dominic
    Nwoye, Milie
    Humaidan, Peter
    Anckaert, Ellen
    Devroey, Paul
    Tournaye, Herman
    FERTILITY AND STERILITY, 2013, 100 (02) : 438 - 444
  • [29] Effect of progesterone/estradiol ratio on pregnancy outcome of patients with high trigger-day progesterone levels undergoing gonadotropin-releasing hormone antagonist intracytoplasmic sperm injection cycles: a retrospective cohort study
    Golbasi, Hakan
    Ince, Onur
    Golbasi, Ceren
    Ozer, Mehmet
    Demir, Mustafa
    Yilmaz, Bulent
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2019, 39 (02) : 157 - 163
  • [30] Luteal phase and clinical outcome after human menopausal gonadotrophin gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization intracytoplasmic sperm injection cycles
    Albano, C
    Smitz, J
    Tournaye, H
    Riethmüller-Winzen, H
    Van Steirteghem, A
    Devroey, P
    HUMAN REPRODUCTION, 1999, 14 (06) : 1426 - 1430